NCT04762472View on ClinicalTrials.gov

Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Atherosclerosis, Coronary
Interventions
DRUG

Montelukast Oral Tablet

i) Montelukast 10mg daily (tablet) orally x 26 weeks

DRUG

Montelukast Placebo Oral Tablet

i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks

Trial Locations (1)

Unknown

The Chinese University of Hong Kong, Department of Medicine & Therapeutics, Shatin

All Listed Sponsors
collaborator

People's Hospital of Chongqing

OTHER

collaborator

Hong Kong University of Science and Technology

OTHER

collaborator

Chongqing Medical University

OTHER

collaborator

University of Sydney

OTHER

lead

Chinese University of Hong Kong

OTHER

NCT04762472 - Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China | Biotech Hunter | Biotech Hunter